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Abstract
Background: Cancer remains one of the leading causes of death worldwide, despite the possibilities to detect early
onset of the most common cancer types. The search for the optimal therapy is complicated by the cancer diversity
within tumors and the unsynchronized development of cancerous cells. Therefore, it is necessary to characterize
cancer cell populations after treatment has been applied, because cancer recurrence is not rare. In our research, we
concentrated on small cancer cell subpopulation (microcells) that has a potential to be cancer resistance source.
Previously made experiments has shown that these cells in small numbers form in specific circumstances after
anticancer treatment.
Methods: In experiments described in this research, the anticancer agents’ paclitaxel and doxorubicin were used to
stimulate the induction of microcells in fibroblast, cervix adenocarcinoma, and melanoma cell lines. Mainly for the
formation of microcells in melanoma cells. The drug-stimulated cells were then characterized in terms of their
formation efficiency, morphology, and metabolic activity.
Results: We observed the development of cancer microcells and green fluorescent protein (GFP) transfection
efficiency after stress. In the time-lapse experiment, we observed microcell formation through a renewal process
and GFP expression in the microcells. Additionally, the microcells were viable after anticancer treatment, as
indicated by the nicotinamide adenine dinucleotide hydrogen phosphate (NADPH) enzyme activity assay results.
Taken together, these findings indicate that cancer microcells are viable and capable of resisting the stress induced
by anticancer drugs, and these cells are prone to chemical substance uptake from the environment.
Conclusion: Microcells are not only common to a specific cancer type, but can be found in any tumor type. This
study could help to understand cancer emergence and recurrence. The appearance of microcells in the studied
cancer cell population could be an indicator of the individual anticancer therapy effectiveness and patient survival.
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Background
Cancer is a major human health problem and remains
the second leading cause of death worldwide, after car-
diovascular disease [1]. In the year 2018 alone, there
were 18.1 million new cancer incidences worldwide, with
more than half of all cases being lethal [2]. Tumor het-
erogeneity and cancer cell polymorphism and differenti-
ation in various developmental stages in the same tumor
make it very difficult to choose the most efficient and
suitable therapy. While significant efforts have already
been made to characterize cancer cell population within
untreated tumors, cancerous cell population after ap-
plied chemotherapy has not been understood. Buiķis and
colleagues have previously shown that human sarcoma
cell cultures treated with thiophosphamide (Thio-
TEPA), a chemotherapeutic agent used to treat breast,
ovarian and bladder cancers [3, 4] exhibit the develop-
ment of unusual small-sized cells, called microcells.
These cells are round or oval, with a small amount of
cytoplasm, and are intensively stained by bromo-2-
deoxyuridine (BrdU) that is thymidine analog and it in-
corporates into DNA and shows cells in S-phase and
methyl green-pyronine that stains nucleic acids both in
DNA and RNA [4–6]. A population of microcells has
also been observed in triple-negative breast cancer histo-
logical samples obtained from patients [7]. Microcells
from patient histological samples stained with Feulgen
assay are characterized by a small nucleus and a high
average optical density, which is proportional to the
amount of DNA in a cell [7]. Microcells have been de-
scribed as a natural tumor component, but interestingly
their relative numbers increase after cancer therapy has
been initiated. Buiķis et al. [8] have proposed a hypoth-
esis explaining the process of microcell development by
sporosis, which is a process of microcell formation from
a damaged tumor macrocell [8]. Indeed, it has been
shown that the number of viable microcells rapidly in-
creases in tumor tissues after anticancer therapy has
been initiated. One defective macrocell may produce one
or several microcells [4, 8].
Microcells are viable and appear to resist cancer treat-
ment. Thus, it is of a great importance to characterize
this cell subpopulation, in order to develop new treat-
ment strategies and improve therapy efficiency. In this
work, we have identified and morphologically character-
ized microcells and their formation after initiation of
anti-cancer treatment with doxorubicin and paclitaxel.
Doxorubicin (DOX) and paclitaxel (PTX) are the most
effective drugs currently used in anticancer therapy of
various types of cancers, for example breast, ovarian,
lung cancers and melanoma [9–11]. DOX is a widely
used anticancer drug that intercalates within DNA base
pairs, causing damage to DNA strands, inhibiting both
DNA and RNA synthesis and thereby arresting cell
proliferation [11, 12]. PTX, on the other hand, is an anti-
microtubular agent. PTX causes abnormal stabilization
of dynamic microtubule polymerization, leading to the
failure of mitosis, proliferation, invasion, and cancer cell
colony formation [10, 13, 14]. In this study we have
identified microcell formation in three different cell
lines: human melanoma (SK-Mel-28), human skin fibro-
blast (HS-68) and cervical carcinoma (HeLa) cells. Fur-
thermore, using 8-anilinonaphthalene-1-sulfonic acid
(ANS)- Ethidium bromide (EtBr), nicotinamide adenine
dinucleotide hydrogen phosphate NADPH assay, and
time-lapse experiments with green fluorescent protein
(GFP) transfection, we have shown that the microcells
are viable and metabolically active. Several studies report
observation of cells which from after chemotherapy;
these cells are metabolically active cells, with high prolif-
eration activity and increasing NADPH, which improves
cell viability and aging escape [15–17]. Various studies
focus on drug-resistant cell populations in aggressive
types of cancer [18–20], but without morphological
characterization of these cells. Melanoma is the most ag-
gressive skin cancer, with poor response to treatment,
with a melanoma cell line study showing DOX chemore-
sistance ability [21]. SK-MEL-28 is a DOX- and PTX-
resistant human melanoma cell line [6, 22, 23].
Methods
Cell lines
Human cervical carcinoma (HeLa), SK-MEL-28 melan-
oma, and HS-68 (human skin fibroblast) cell lines were
acquired from the American Type Culture Collection
(ATCC) and maintained in a culture medium consisting
of Dulbecco’s modified Eagle’s medium (DMEM;
Thermo Scientific, IL, USA) supplemented with 10%
fetal bovine serum (FBS). All cell lines were seeded as
monolayer on cover glass into 24-well plates with an ini-
tial density of ~ 1 × 105 cells per well and grown in a hu-
midified atmosphere containing 5% CO2 at 37 °C.
DMEM supplemented with 10% FBS and 10mg/mL of a
penicillin/streptomycin solution (all from Sigma-Aldrich,
MO, USA).
To our knowledge, the microcells were so far only ob-
served in human sarcoma (HT-1080) and human cer-
vical carcinoma (HeLa) cell lines and Djungarian
hamster fibroblastomas cell line 4/21 [4, 8, 24]. There-
fore, we used three cell lines to determine if microcells
could be forming in other cancer (HeLa, SK-MEL-28)
and non-cancer (HS-68) cell lines. In this study we used
the HeLa cell line, to which is known that microcells
formation is initiated by applied stress factors. The sec-
ond used cell line is a human fibroblast cell line (HS-68)
described as normal cells, and the third cell line is mel-
anoma cells which are quite aggressive skin cancer.
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Stress factors
Stress factors were applied to cancer microcell forma-
tion. Cell lines HeLa, HS-68, and SK-MEL-28 were
treated for 24 h with doxorubicin (DOX; 50mg; TEVA)
at a final concentration of 2.5 μM or with paclitaxel
(PTX; 6 mg/mL; TEVA) at a final concentration of
0.7 μM at 37 °C in a 5% CO2 atmosphere. The DOX and
PTX were not used together. After treatment, the
DMEM was replaced with fresh medium, and the cells
were cultivated for another 24 and 48 h at 37 °C in a 5%
CO2 atmosphere.
The HeLa cell line was treated with methanol (Sigma
Aldrich, USA) at final concentration 7.5% for 1 h at
37 °C in 5% CO2 atmosphere. After the treatment, cells
were cultivated in fresh DMEM medium for 6 h. The
cultivated cells were fixed with 4% formaldehyde solu-
tion for 10 min at room temperature.
NADPH test for cell metabolic activity
Nicotinamide adenine dinucleotide hydrogen phosphate-
diaphorase (NADPH-d) is an enzyme that can reduce ni-
tro blue tetrazolium (NBT) dye to the visible reaction
product formazan [25]; the reaction involves hydrogen
transfer from the substrate at presence of NADPH, to a
hydrogen acceptor. Initially, SK-MEL-28 cells were culti-
vated for 24 h with 0.7 μM of PTX, then the medium
was changed and the cells were cultivated for another
24 h. The NADPH test started with pre-fixation for 1
min with a 4% formaldehyde solution (Sigma-Aldrich,
MO, USA), then cells were carefully washed two times
with 1.5M TRIS buffer saline and incubated for 30 min
in the incubation medium (2.5 mL of 1.5 M TRIS buffer
saline, 1.5 g of sucrose, 0.5 mL of nitro blue tetrazolium
(Sigma-Aldrich, MO, USA), and 0.9% NaCl to 10mL).
NADPH substrate (β-Nicotinamide adenine dinucleotide
phosphate reduced sodium salt hydrate; SERVA,
Germany) was administered to the solution shortly be-
fore incubation. The reaction was stopped with a 4% for-
maldehyde solution fixation for 10 min at room
temperature, washed with distilled H2O and covered
with coverslips using CV ultra-mounting medium (Leica
Biosystems, Nussloch, Germany). NADPH diaphorase
activity was seen as dark blue or black spots in the cell
cytoplasm. The NADPH activity was scored semi-
quantitatively by two independent observers using ZEISS
microscopy Camera Axiocam 202 mono, where 0
points- activity was not detected; 1 point- low activity; 2
points- activity was detected in average level; 3 points
high activity, but not in a whole cell or sample; 4 points
strong activity in the entire cell or sample.
ANS-ethidium bromide staining
The 8-anilinonaphthalene-1-sulfonic acid (ANS) –
ethidium bromide (EtBr) staining technique was used
to detect presence of proteins and nucleic acids in
cells. ANS is a staining protein at hydrophobic site of
a protein, it fluoresces in a blue light [26, 27], while
EtBr fluoresces in a red light, thereby revealing DNA
and RNA [28].
HeLa cells were seeded in monolayers on a coverslip
at a density of ~ 1 × 105 cells per well and grown in a hu-
midified atmosphere 1containing 5% CO2 at 37 °C.
DMEM growth medium was supplemented with 10%
fetal bovine serum and 10 mg/mL of a penicillin/strepto-
mycin solution (all from Sigma Aldrich, USA). When
cell density was 80–100% on the monolayer, a final con-
centration of 7.5% methanol (Sigma-Aldrich, MO, USA)
was added. Cells were incubated for 1 h at 37 °C in a 5%
CO2 atmosphere. After treatment, the cells were culti-
vated in fresh DMEM for 6 h. The cultivated cells were
fixed with a 4% formaldehyde solution for 10 min at
room temperature, then stained with 5 μg/mL of ANS
(Sigma-Aldrich, MO, USA). The dye solution was kept
in the dark, poured the cover slide with cells, incubated
for 10 min at room temperature, before being drained
without washing. EtBr (3 μg/mL; Sigma-Aldrich, MO,
USA) was poured on the cover slide with the cells, incu-
bated for 10 min at room temperature, kept in the dark,
and then drained without washing. The cells were dried
in the air, and covered with coverslips using CV ultra-
mounting medium (Leica Biosystems, Nussloch,
Germany). ANS–EtBr fluorescence was visualized using
a three-band blue, red, and green (Leica BRG) optical fil-
ter and a Leica DM1000B microscope qualitatively
scored blinded by two independent observers as negative
or positive staining.
The neutral red uptake assay (NRU)
Neutral red uptake assay is used for cytotoxicity detec-
tion. The principle of this assay is based on the detection
of viable cells via the uptake of the dye neutral red [29].
SK-MEL-28 cells were seeded into the 24-well plate on
the coverslips at the concentration of ~ 1 × 105 cells per
well and grown in a humidified atmosphere containing
5% CO2 at 37 °C. Reaching 80% of confluency cells were
treated with paclitaxel (PTX; 6 mg/mL; TEVA) at a final
concentration of 0.7 μM at 37 °C in a 5% CO2 atmos-
phere for 24 h. After the treatment, the DMEM was re-
placed with fresh medium, and the cells were cultivated
for another 24 at 37 °C in a 5% CO2 atmosphere. Se-
quentially neutral red (NR, Sigma-Aldrich, Taufkirchen,
Germany) was added to control and treated cells for 3 h
incubation. After 3 h the staining solution was removed,
cells were rinsed three times with PBS. Then cells were
fixed with 4% formaldehyde solution for 10 min in room
temperature and rinsed three times with PBS. Coverslips
were removed from the 24-well plate coated with CV
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ultra-mounting medium and analyzed under a
microscope.
Cell transfection and GFP expression time lapse
Initially, SK-MEL-28 cells were seeded on glass-bottom
24-well plates (Cellvis, CA, USA) at a concentration of
~ 1 × 105 cells per well and grown in a humidified at-
mosphere containing 5% CO2 at 37 °C. DMEM cultiva-
tion medium was supplemented with 10% fetal bovine
serum and 10 mg/mL of a penicillin/streptomycin solu-
tion (all from Sigma-Aldrich, MO, USA). When the SK-
MEL-28 -melanoma cells reached 70–80% confluence,
the medium was replaced with fresh growth medium
containing 10% FBS (Sigma-Aldrich, MO, USA).
A transfection mix for one sample was prepared using
1 μg of plasmid pcDI-EGFP (6837 bp) containing GFP
gene diluted in 100 μL of serum-free DMEM with an
additional 2 μL of TurboFect™ reagent (Thermo Scien-
tific, IL, USA), according to the manufacturer’s protocol
[30]. A plasmid pcDI-EGFP allows GFP expression in vi-
able cells. The plasmid and TurboFect™ complex were
incubated for 15 min at room temperature. Then, 100 μL
of the TurboFect™/plasmid mixture drop was used to
transfect each well of the plate. The cells were grown for
24 h in the presence of the plasmid; after the incubation
period, the growth medium was replaced with DOX (50
mg; TEVA) at a final concentration of 2.5 μM into each
well, and cultivated for 24 h at 37 °C in 5% CO2, nor-
moxia, using a confocal laser microscope (Leica SP8
Confocal, Leica, Wetzlar, Germany) cell cultivation
chamber. Then the medium was changed for a fresh
medium without DOX.
The confocal laser microscope transmitted light and
the fluorescent light detectors were equipped at the
argon laser line of 488 nm, the time lapse function was
used for time lapse imaging. Images were taken every
120 min after doxorubicin administration and examined
for 72 h. GFP was excited by 488 nm laser line and the
emission was detected at 510 nm.
TSG101 antigen expression detection
SK-MEL-28 cells were cultivated on coverslips at the
concentration of ~ 1 × 105 cells per well and grown in a
humidified atmosphere containing 5% CO2 at 37 °C.
Reaching 80% of confluency cells were treated and
microcell formation induced with PTX at a final concen-
tration of 0.7 μM at 37 °C in 5% CO2 atmosphere for 24
h. After the treatment, the DMEM was replaced with
fresh medium, and the cells were cultivated for another
24 at 37 °C in a 5% CO2 atmosphere. Then cells were
fixed with 4% formaldehyde solution for 10 min in room
temperature and rinsed with PBS two times for 5 min
and antigen retrieval was done with 0.2% Triton X-100.
After that samples were rinsed with PBS three times for
5 min and one time with PBS/Tween 20 for 5 min. Se-
quentially samples were blocked with 2% BSA/PBS for 1
h in room temperature. Blocking solution was decanted
without washing and added TSG101 (GTX635396; Gen-
Tex, NordicBioSite, Finland) monoclonal rabbit anti-
human primary antibody diluted 1:50 in 1% BSA/PBS,
and incubated overnight at 4 °C in a humidified cham-
ber. Samples were then washed trice with PBS for 5 min
and once with PBS/Tween 20 for 5 min and covered
with Alexa fluor 488 (ab150077, Abcam, CA, USA) goat
anti-rabbit secondary antibody diluted 1:200 in 1% BSA/
PBS, and incubated for 1 h in a humidified chamber in
the dark. Samples were washed trice with PBS for 5 min
and once with PBS/Tween 20 for 5 min. Cell nuclei were
counterstained with 1 μg/mL DAPI for 1 min and finally
coated with CV ultra-mounting medium and analyzed
under a microscope.
Determination of cells number
The cells count was determined using a Leica DM1000B
microscope (Leica Microsystems) with a 40× objective
(dry, plan apochromatic, with a numeric aperture of
0.85). The microcell count and the whole number of
HeLa, HS-68, and SK-MEL-28 cells in the three experi-
ments in at least ten fields of view were obtained. The
total number of counted cells was 1060 cells at each
time point: 24, 48, and 72 h after applied therapy.
Microscopy and image analysis
A Leica DM1000B microscope (Leica Microsystems,
Wetzlar, Germany) with 63× objective (oil, plan apo-
chromatic, with a numeric aperture of 1.40) equipped
with a Leica DFC400 (Leica Microsystems, Wetzlar,
Germany) digital camera and ZEISS Axiolab 5 micro-
scope with 63×/0.85 objective (oil, N-Achroplan, Ph3
M27; ZEISS, Jena, Germany) with ZEISS Microscopy
Camera Axiocam 202 mono (ZEISS, Jena, Germany)
were used for microscopy of the samples. For image ana-
lysis and processing, Image-Pro® plus the Proven Solu-
tion™ software, version 4.0, and LAS X lite (Leica
Microsystems, Wetzlar, Germany) and ZEN 3.0 Blue lite
(ZEISS, Jena, Germany) were used.
Transmission Electron microscopy
Transmission electron microscopy was done in previous
pilot experiments inducing microcells by stress factors.
In our study we decided to use the archive materials of
TEM. The cell line 4/21 was seeded in 24 cm2 Karell
flasks with a density of ~ 3 × 105 cells per well and
grown in Eagle medium supplemented (Sigma-Aldrich,
MO, USA) with 10% FBS and 1% penicillin/streptomycin
(growth medium) in a humidified atmosphere containing
5% CO2 at 37 °C. Cells were treated with Thio-TEPA at
a final concentration 20 μg/mL for the 24 h. After
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treatment, the medium was removed and washed with
medium without serum, and fresh growth medium was
added and incubated in for the 24 h. The incubation
medium was removed and 4 °C 2.5% glutaraldehyde so-
lution prepared in PBS at 4 °C was added for the cell
sample preparation for electron microscopy. The cells
were fixed for 15 min in the 2.5% glutaraldehyde solu-
tion. Sequentially the cell monolayer was detached gen-
tly using a cell scraper and collected in a test tube, and
centrifugated for 10 min at 200 g. Then cells were
washed twice with PBS at 4 °C and postfixed with 2% os-
mium acid solution prepared in PBS for 10 min. The pel-
let was dehydrated in 70% ethanol and embedded in
Epon (Epoxy embedding medium; Sigma-Aldrich,MO,
USA). Ultrathin sections were contrasted by uranylace-
tate and lead citrate, and examined using an electron
microscope JEM-100B (TEM, Japan).
Statistical analysis
The number of microcells in the control (untreated) and
treated cells was compared using two-tailed Student’s t-
test for unpaired samples was used. Statistical
significance of difference of means were calculated
where appropriate. The differences were considered sig-
nificant at p ≤ 0.05. The percentages were counted, as-
suming a total cell count of 1060 being 100%.
Results
Initiation of microcell formation using paclitaxel and
doxorubicin
The microcells were previously observed in human sar-
coma (HT-1080) and human cervical carcinoma (HeLa)
cell lines [4, 8]. The HeLa cell line was chosen as cell
line to which is known that microcells formation is initi-
ated by applied stress factors, such as chemotherapeutic
drugs Thio-TEPA [4]. Therefore, to prove that micro-
cells development is not specific to one cell line type, we
used three different cell lines were used to determine if
the microcells formed in other cancer and non-cancer
cell lines.
In this study, we used the HeLa cell line, and micro-
cells were initiated by applying DOX, PTX or methanol
as stress factor. Additionally, the human fibroblast cell
line HS-68, described as normal cells, and the melanoma
cell line, which is quite an aggressive skin cancer, were
used [23].
After the SK-MEL-28 cell cultivation for 48 h follow-
ing chemotherapy (in this case, treatment with PTX),
the cell samples were examined (Fig. 1). The control
sample (untreated) cells were spindle-shaped with a
round and elongated nucleus (Fig. 1A). We observed
small, round, and intensively stained cells, which formed
after PTX therapy in the SK-MEL-28 cell line (Fig. 1B).
In contrast, when therapy was not used, microcells were
not seen at all (Fig. 1A). The increasing number of
microcells shows the cell’s ability to survive the impact
and effects of medication.
The 1060 cells were counted in this study in each of
the used cell lines— HeLa, HS-68, and SK-MEL-28 cells.
In the used HeLa and SK-MEL-28 cell lines under inves-
tigation, the microcells (shown as blue dots in Fig. 2)
were mostly observed after anticancer treatment with
PTX and DOX (72 h; Fig. 2). The microcells showed an
increasing tendency in the cell population of the HeLa
Fig. 1 Microcell formation in SK-MEL-28 cells after paclitaxel (PTX) treatment for 48 h. (A) Untreated SK-MEL-28 cells (control sample) and phase
contrasts (PhC); cell nuclei are stained with DAPI (blue) and are overlaid (PhC/DAPI). (B) SK-MEL-28 PTX-treated cells, PhC. The white arrows show
the microcell formation. The cell nuclei are stained with DAPI (blue) and are overlaid (PhC/DAPI). The scale bar is 20 μm
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Fig. 2 Increase in the number of microcells after applied therapy. Cells were counted after 24, 48, and 72 h following doxorubicin (DOX) and
paclitaxel (PTX) treatment. The total number of counted cells was 1060 cells Microcells—blue dots representing each individual cell out of the
1060 counted cells. In HS-68, the fibroblasts cells, the increase in the number of microcells was small: One of the 1060 cells after treatment. Only
in the cancer cell lines (HeLa and SK-MEL-28) were microcells evaluated in the control (Ctrl) untreated cells and forty-eight hours after applying
PTX and DOX, there was a tendency for the microcells count increase
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cell line. The highest number of microcells was observed
72 h after DOX treatment (18 microcells out of 1060
cells) in the HeLa cell line (Fig. 2): 1.57% from all
counted cells, and the percentage increase was statisti-
cally significant (Table 1). Interestingly, the number of
HeLa microcells after PTX treatment decreased, as com-
pared to 48 h post-treatment. SK-MEL-28, the human
skin melanoma cells, were treated with PTX. The largest
number of microcells in SK-MEL-28 (nine microcells
out of 1060 cells) was observed after 48 h after PTX
treatment (Fig. 2), which is up to 1% (p < 0.016) of the
total cell count (Table 1). In the fibroblast cell line (HS-
68), no microcells were observed as expected. After ap-
plied treatment with DOX or PTX, the increase in the
number of microcells in non-cancerous HS-68 cell line
was small: One of the total counted cells. Results of this
experiment indicate that microcells are natural compo-
nents of a tumor, as these cells were detectable in un-
treated cancer cells and the number of microcells
increase in both cervical carcinoma and melanoma cells,
following DOX or PTX treatment. However, it appears
that microcell formation in cancerous cell lines is stimu-
lated by applied chemotherapy, as microcell count in-
creases significantly after treatment with DOX or PTX,
compared to non-cancerous HS-68 cell line.
Proteins and nucleic acids in early formed microcells
ANS-EtBr staining method was used to identify proteins
and nucleic acids in the microcell. ANS stains proteins –
shown in blue and EtBr stains nucleic acids – stains red.
Methanol stimulates apoptosis, and it was used to com-
pare if the microcell formation observed as well as after
chemotherapeutic drugs in HeLa cell line (known that
microcells formatting). At first, microcells were observed
after 6 h of exposure to 7.5% methanol (Fig. 3), which
had a toxic effect on HeLa cell viability. ANS dye and
ethidium bromide (EtBr) were used to identify presence
of the proteins and nucleic acids in the microcells
(Figs. 3). As shown in Fig. 3A, macrocells contain a
smaller number of proteins compared to microcells. This
indicates that the protein synthesis in macrocells is
weak. When the microcells segregated from the macro-
cells, the microcells contained proteins (Fig. 3A, C, white
arrow) and a small amount of nucleic acid (Fig. 3B, C).
Although the microcells contained both proteins and
nucleic acid, this is not yet indicated that the cells are vi-
able. Therefore, it is important to research therapy sur-
viving cells, determining the functional properties and
markers characterizing microcells.
Microcell formation and GFP expression after doxorubicin
therapy: time lapse experiment
ANS-EtBr staining experiment has shown that the
microcells contained both proteins and nucleic acids,
however it was not clear if these cells are viable and can
proliferate. Therefore, we set to determine if microcells
are alive and able to express proteins. We have used
GFP expression as a marker for cell viability. For follow-
ing experiments, we used the SK-MEL-28 cell line to
looking forward microcell formation in the one of the
most aggressive skin cancers, melanoma.
The 72 h time lapse experiment (see Materials and
Methods for details) showed that 24 h after chemo-
therapy, the cancer cell morphologically behaved
similar to apoptotic cells. Specifically, cell was
rounded (Fig. 4), their cytoplasm produced blebs (10
h; Fig. 4), and the cell formed apoptotic-like bodies
(12–14 h; Fig. 4). However, every 2 h in time lapse
images following this, we observed that a microcell
categorized as an apoptotic cell was capable of self-
regeneration. This process appears to be visually
similar to active endocytosis, when a cell is hosting
particles from the extracellular space and regenerates
(transforms) into a microcell. Herein, the microcells
displayed the following morphological features:
roundish and small-sized cells (approximately 3–
5 μm) with endocytic ability and, finally, GFP expres-
sion (16–20 h; Fig. 4; see Supplementary file 1), indi-
cating viability and activity. The results of this
experiment showed that only a part of total cell
population expresses GFP, however microcells are
also capable of GFP expression, which indicates that
these cells have retained the necessary machinery for
protein expression and thus are viable and metabol-
ically active.
Table 1 Microcells count 24, 48 and 72 h after DOX (Doxorubicin) and PTX (Paclitaxel) treatment in HS-68, HeLa and SK-MEL-28 cell
lines































HS-68 NA 0.09 0.324 NA NA NA 0.09 0.324 0.09 0.324 NA 0.09 0.324 0.09 0.324
HeLa 0.28 0.46 0.437 0.37 0.684 0.19 1.11 0.013 0.09 0.560 0.56 1.57 0.047 0.00 0.023
SK-MEL-
28
0.28 0.19 0.700 0.09 0.302 0.09 0.65 0.037 0.83 0.016 0.09 0.37 0.157 0.56 0.151
Significant microcell count increase p values (≤ 0.05) are highlighted in bold. p values obtained by Student’s t test. Ctrl control, NA no microcells detected
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Detection of the microcell metabolic activity using NADP
H test
To assess the viability of cells after anticancer treatment,
we used an NADPH test in vivo. PTX, as an anticancer
compound, and the SK-Mel-28 cell line were chosen for
this experiment. NADPH test shows the metabolic activ-
ity of the cell. Cell’s oxidation processes related to bio-
synthesis take place in two systems from mitochondria
to the endoplasmic reticulum. Hydrogen ion is trans-
ferred through the cytochrome system (cytochrome 450)
and cell viability is shown [31]. In this experiment,
NADPH activity was detected. NADPH is an enzyme
that can reduce nitro blue tetrazolium (NBT) dye to the
visible reaction product formazan —the reaction in-
volves hydrogen transfer from the substrate, NADPH, to
the hydrogen acceptor [25, 32]. The untreated SK-MEL-
28 cells exhibited metabolic activity, as expected
(Fig. 5A). However, the PTX-treated macrocells had de-
creased metabolic activity, except for the microcells,
which exhibited high NADPH activity (Fig. 5B). Micro-
cells are able to breathe, meaning these cells are not
apoptotic and thus cannot die. Consequently, microcel-
lular protein expression is not excluded; this metabolic
activity indicates that microcells cells resist the
treatment.
Cell viability detection using NRU
Neutral red uptake (NRU) assay is used for cytotoxicity
detection. The principle of this assay is based on the de-
tection of viable cells via the uptake of the NRU [33, 34].
The untreated SK-MEL-28 cells (Fig. 6A) presented NR
up take via active transport – endocytoses, meaning
these cells are viable. Otherwise, PTX treated SK-MEL-
28 (Fig. 6B) cell presented lack or no NRU at all, that
means cells are non-viable. In turn, the microcell (Fig.
6B, red arrow) presented intensively NR uptake. As it is
seen in phase contrast (Fig. 6B, PhC) around the micro-
cell is empty area that indicates to rise endocytosis and
cell viability [35].
Microcells are not expressing TSG101 antigen
TSG101is a biogenesis factor associated with extracel-
lular vesicles [36]. In this studyTSG101 expression is
evaluated in microcells to differentiate microcells
from extracellular vesicles. Untreated SK-MEL-28 cells
(Fig. 7A) expressed TSG101.The expression of
TSG101 is seen as a collection of small green dots
(Fig. 7A, TSG101). Antigen is expressed in cell cyto-
plasm (Fig. 7A, PhC) near the nucleus (Fig. 7A,
DAPI/TSG101/PhC). In turn, PTX treatment induced
microcell formation in the SK-MEL-28cell line (Fig.
7B, DAPI). Nevertheless TSG101 (Fig. 7B, TSG101) is
not expressed in microcells but in the cell cytoplasm
(Fig. 7B, PhC) is localized near the nuclei (Fig. 7A,
DAPI/TSG101/PhC). This experiment showed that
the microcells are not extracellular vesicles which ex-
pressing TSG101.
TEM microcell morphology
From our pilot experiments at the ultrastructural level
microcell example after Thio-TEPA induction in the
Djungarian hamster cell line 4/21 is shown in Fig. 8. It is
seen that a microcell is a small cell with an electron-
dense cell nucleus, nuclear envelop, cell membranes, cell
cytoplasm, and organoids. In the cell cytoplasm are ribo-
somes, visible as dark spots in the cell cytoplasm. Fig-
ure 8A shows a newly formed microcell. It is
characterized by the increased relationship between the
cell nucleus and the cytoplasm. In the cell cytoplasm are
ribosomes, seen as dark spots. The chromatin where het-
erochromatin, known as inactive chromatin, is part of
the cell nucleus is in sufficient quantity suggesting to
partly differentiated cell.
In contrast, microcell is shown in Fig. 8B shows in-
creased ratio of the cell nucleus to cytoplasm. Microcell
is characterized by the nucleoli and euchromatin, which
occupy most of the cell nucleus suggesting to young cell
with acquired stem cell properties.
Fig. 3 Microcell formation in the HeLa cell line after treatment with 7.5% methanol. (A) Microcell formation (blue protein body (ANS), white
arrow); (B) an EtBr-stained microcell (white arrow) in contact with a macrocell (white star); (C) overlay (A, B). ANS–EtBr staining 6 h after treatment.
The scale bar is 25 μm
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Discussion
In this work we induced microcells in human cancer
cell (SK-MEL-28 and HeLa) lines and human fibro-
blasts (HS-68) used chemotherapeutic drugs DOX
and PTX acting to cells 24 h. We observed that
microcells also occur HeLa cells after 6 h 7.5% metha-
nol treatment.
We have showed that microcells develop come into
being from apoptotic macrocells, evolving from apop-
totic bodies. The microcell formation in this work was
observed after cancer cell exposure to chemotherapy or,
described by cell morphological changes. Our findings
are in agreement with results reported by Buiķis et al.
[8] who showed that microcells can form successfully
Fig. 4 Microcell development and GFP expression after 24 h doxorubicin (DOX) treatment in SK-MEL-28 cells. The images were taken every 2 h;
the red squares mark the region of interest (ROI). At 0, 2, 4, 6, 8, and 10 h, the cell was rounded, looking morphologically similar to the beginning
of apoptosis (white arrow); at 12, 14, 16, and 18 h, the start of development of microcells (16–18 h, white arrow) and the expression of EGFP
could be observed. At 20 h (white arrow), microcells were fully developed and expressed GFP. The scale bar is 100 μm
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from damaged or fatally damaged macrocells via the
sporosis mechanism. Newly developed microcells are in-
dependent and mobile, with endocytosis activity. Micro-
cells with a diameter from 2.5 to 5 μm, developed via the
sporosis mechanism, could possibly avoid anticancer
therapy [37].
Similarly to microcells, Raju cells, nucleolar aggre-
somes (NoAs), and Bonghan microcells (BH-MCs) have
also been observed in cancer cell lines after anticancer
treatment. Sundaram et al. have observed the cell forma-
tion of mitotic colonies on the monolayer in a cell cul-
ture after treatment with etoposide (VP-16) or X-rays
[38]. On day 14 after treatment initiation, from the
mother cell in a process called neosis, the number of
Raju cells raised to approximately 10, with a diameter of
6–10 μM; however, only 8% of them were unable to sur-
vive [38]. Raju cells are able to live for 8 weeks after mi-
totic crisis, after new Raju cell formation from polyploid
cells [38]. Another study showed that after treatment
with VP-16, NoAs are formed on day five; these NoA
cells were shown to contain fibrillarin, rDNA, and peri-
centric heterochromatin [39]. Unlike microcells and Raju
cells, BH-MCs have observed in normal tissues, such as
the small intestines and blood cell leukocytes of rats
[40]. A BH-MC is a small-sized cell with the ability to
divide and pluripotent differencing features, similar to
adult stem cells [40]. The differences between microcells
and BH-MCs are that microcells are generated from
cancer cells, whereas BH-MCs form from micronuclea-
tion during normal physiological processes [4, 40].
The differences between microcells, Raju cells, and
NoAs are that microcells develop from macrocells 24–
48 h after antitumor treatment [4], whereas Raju cells
and NoAs develop from the polyploid cell tree up to 7
days after anticancer treatment [8, 38, 39]. Elevated
microcell phagocytic ability has observed using carmine
red and Indian ink, suggesting their metabolic activity
[24]. Microcell formation is a rare process that occurs in
less than 1 % of cases [24]. The number of microcells in
the population of cell lines considered was small, ap-
proximately 1%. Drug-tolerant persister (DTP) cancer
cell populations that constitute approximately 0.3–5% of
the initial cell population after erlotinib drug are de-
scribed in other studies [20, 41]. DTP cells are character-
ized as non-genetic anticancer drug-resistant cells,
especially against chemotherapy [20, 41]. Numerous an-
ticancer drugs, such as paclitaxel and doxorubicin, which
were used in this study, as well as methanol, cause cell
stress, which creates DNA damage and damage to cellu-
lar membranes, interrupting cell homeostasis, and indu-
cing apoptosis [42–44]. The cell membrane after
treatment with UV radiation and DOX or PTX becomes
permeable [43, 45], and it becomes easier to transfect a
plasmid DNA into the cells. To avoid damage, cells
transform their architecture to a spherical shape during
mitosis; this process is controlled by changes in the actin
cytoskeleton. However, repairing DNA damage during
mitosis is dangerous to cells and could incorrectly affect
the results with chromatids separated in anaphases, thus
promoting genome instability and cancer genesis [46].
The development and homeostasis in an organism en-
able apoptosis, a fundamental and complex biological
process that destroys unwanted damaged cells [47]. A
typical apoptosis scene shows blebbing of the plasma
membrane, nuclear fragmentation, chromatin condensa-
tion, which includes chromatin parts on the nuclear
membrane, and formation of apoptotic bodies [33]. Al-
though an enormous amount of data indicate that cyto-
toxic drugs induce and activate apoptosis initiation
machinery and the cellular stress response, many ques-
tions remain unanswered. For instance, the opinion that
apoptosis represents the principle of the mechanism by
which tumor cells are killed as a result of cancer therapy
may not be universally true, as previously proposed by
Herr and Debatin [48]. Microcells are small-sized, round
or oval cells with small cytoplasm. Microcells increase in
Fig. 5 Microcell metabolic activity determined by a NADPH test using SK-MEL-28 cells 48 h after treatment with paclitaxel (PTX). (A) Untreated
cells, all NADPH-positive, dark spots; (B) PTX-treated cells, microcell (red arrow), NADPH-positive cell. The scale bar is 20 μm
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count after 24 h of treatment with anticancer drugs; the
highest number of microcells was observed 48 h after ap-
plying chemotherapy, with the microcells tending to in-
crease in number after chemotherapy, irradiation, or
immunotherapy [4, 8]. There is a hypothesis that a
microcell forms from a perished macrocell [8]. We
showed that in the early stages of microcell formation,
cells mainly contain proteins (Fig. 2). ANS solution is a
universal and widely used compound for the study of
proteins [49]. When microcells are completely formed,
nucleic acid is detectable as well (Fig. 3B). The microcell
formation under applied therapy is observed in the other
research, where is shown that the microcell contain ribo-
some like particles, nucleus with pronounced functional
activity [50]. As it is seen in electron microscopy image
(Fig. 8), the microcell has specific organelles characteris-
tic to viable cell. DNA damage, which is caused by oxi-
dative stress, promotes tumorigenesis [51]. The
metabolic activity of these cells can be demonstrated by
a NADPH test. NADPH performs duties as an antioxi-
dant substrate for the thioredoxin and glutathione anti-
oxidant systems, thereby reducing the level of hypoxia in
a cell [18, 52]. Paclitaxel, as an anticancer drug, is not
only involved in the hyper-stabilization of microtubules
Fig. 6 Microcell viability detection using NRU assay in SK-MEL-28 cell line after applied PTX for 48 h. (A) Untreated SK-MEL-28 cells with positively
NR uptake, NRU – NR uptake, PhC- phase contrasts, NRU/PhC - NRU and PhC overlay; (B)SK-MEL-28 cell treated with PTX with significant NR
uptake in microcells (NRU, red arrow), NRU – NR uptake, PhC – phase contrast, NRU/PhC - NRU and PhC overlay. Microcell showed intensive NR
uptake and this small single cell is localized nearby microcell debris (PhC). The scale bar is 20 μm
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and the inhibition of cytoskeletal restructuration, an in-
crease in metabolic oxidative stress and NADPH oxidase
is also associated with paclitaxel’s anticancer effect [53].
NADPH, as a reducing agent, is required for anti-
oxidative defense systems—it is a universal electron
donor in reductive biosynthesis and detoxification of the
cell [15]. We observed a decrease in NADPH activity
after anticancer treatment and identified microcells with
high NADPH activity. NADPH is produced by metabol-
ically active cells, and this enzyme indicates cell viability
Fig. 7 TSG101expression in SK-MEL-28 cell. (A) Untreated SK-MEL-28 cells expressed TSG101 (green) marker in their cytoplasm (PhC- phase
contrast) localized nearby nucleus (DAPI, blue). Cell nuclei are stained with DAPI (blue) and the last figure in column is overlaid (DAPI/TSG101/
PhC); (B) Paclitaxel (PTX) treated SK-MEL-28 after 48 h. Cell nuclei are stained with DAPI (blue), cells are captured in phase contrast (PhC) and
overlaid (DAPI/TSG101/PhC). After PTX treatment microcell formation was induced (DAPI, blue), nevertheless TSG101 (green) is not expressed in
microcells but nearby nuclei. The scale bar is 20 μm
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[54, 55]. Moreover, this indicates that microcells are
metabolically active after PTX treatment. For the NADP
H test we used 1 min pre-fixation with 4% formaldehyde
solution to reduce activity of NADPH diaphorase activity
as NADPH activity in the microcell is very strong. This
indicates the rising metabolism of the mircocell after the
applied stress. Abid et al. described NADPH oxidase re-
quirement for endothelial cell proliferation and migra-
tion activity [56]. NADPH has an essential role in
reducing ribonucleotides into deoxyribonucleotides by
ribonucleotide reductase; accordingly, it is involved in
DNA synthesis by implication [15]. Newly formed
microcells are easier to transfect, as they show EGFP ex-
pression similarly to other cells. In some research, can-
cer cells uptake DNA molecules from the cultivation
medium to which they are added, more so than non-
cancer cells [57, 58]. As described by Kong et al., cancer
cell molecule uptake occurs through endocytosis, and
this process does not occur in normal cells [57]. In other
research, it has been proven that nanoparticles accumu-
late in cancer microcells, and that microcells have higher
endocytosis capability [9]. There are drug-tolerant can-
cer cells without phenotypic mutation, and these cells
are able to proliferate after applying therapy. However,
there is a subpopulation that could be a rare mutation
causing drug resistance, and these cells can proliferate
during anticancer drug effects [19, 59]. In our research,
we observed microcell induction, and the number of
microcells increased 48 h after applying chemotherapy.
In further research, it is important to pay attention to
this cell type as a feature of the mechanism of drug re-
sistance or drug-tolerant cells.
Conclusions
Herein, we characterized microcells morphologically.
The number of microcells increased following the appli-
cation of therapy, and these cells were natural compo-
nents of tumors. Microcells are a subpopulation of
cancer characterized by anticancer drug resistance.
Therefore, analysis of the microcell population in a
tumor undergoing anticancer treatment could be a
strong prognostic factor for a patient’s survival, and
could be a potential regenerator of cancer cells after the
death of the tumor itself.
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